title: Risk factors of recurrence of macular oedema associated with branch retinal vein occlusion after intravitreal bevacizumab injection.
abstract: To identify risk factors of recurrence of macular oedema in branch retinal vein occlusion (BRVO) after intravitreal bevacizumab (IVB) injection.
  
  
  
  The records of 63 patients who underwent IVB injection for macular oedema secondary to BRVO with at least 6 months of follow-up were reviewed. Patients were evaluated at baseline with fluorescein angiography (FA), optical coherence tomography (OCT) and ultra-wide-field fundus photography (WFP). During follow-up, OCT and WFP were repeated. The area of retinal haemorrhage, central retinal thickness (CRT), area (mm2) of capillary non-perfusion within the 1 mm (NPA1), 1-3 mm and 6 mm zones of the ETDRS circle, foveal capillary filling time, degree (°) of foveal capillary network destruction and FA pattern were analysed.
  
  
  
  Macular oedema recurred in 41 of 63 (65.1%) eyes after initial IVB injection. A binary logistic regression model showed that NPA1 (OR=434.97; 95% CI=5.52 to 34262.12, p=0.006) and initial CRT (OR=1.004; 95% CI=1.000 to 1.008, p=0.015) were significantly associated with the recurrence of macular oedema. Receiver operating characteristic curve analysis identified an NPA1 of 0.36 mm2(AUC: 0.735, sensitivity: 70.7%; specificity: 63.6%) and an initial CRT of 570 µm (AUC: 0.745, sensitivity: 63.4%; specificity: 77.3%) as cut-off values for predicting recurrence of macular oedema.
  
  
  
  Patients with BRVO with non-perfusion of more than half of the 1 mm zone of the ETDRS circle or with an initial CRT >570 µm should be closely monitored for macular oedema recurrence within 6 months of IVB injection.
authors.affiliation: Department of Ophthalmology, Korea University College of Medicine, Seoul, South Korea.
authors.forename: Jun Ho
authors.initials: JH
authors.lastname: Yoo
authors.affiliation: Department of Ophthalmology, Korea University College of Medicine, Seoul, South Korea.
authors.forename: Jaemoon
authors.initials: J
authors.lastname: Ahn
authors.affiliation: Department of Ophthalmology, Korea University College of Medicine, Seoul, South Korea.
authors.forename: Jaeryung
authors.initials: J
authors.lastname: Oh
authors.affiliation: Medical Science Research Center, Korea University College of Medicine, Seoul, South Korea.
authors.forename: Jaehyung
authors.initials: J
authors.lastname: Cha
authors.affiliation: Department of Ophthalmology, Korea University College of Medicine, Seoul, South Korea.
authors.forename: Seong-Woo
authors.initials: SW
authors.lastname: Kim
mesh_terms: D000328:Adult; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000008:administration & dosage*; D000068258:Bevacizumab / Q000008:administration & dosage*; D002196:Capillaries / Q000473:pathology; D005260:Female; D005584:Fovea Centralis / Q000098:blood supply; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000188:drug therapy* / Q000209:etiology / Q000473:pathology; D008875:Middle Aged; D012372:ROC Curve; D012008:Recurrence; D012170:Retinal Vein Occlusion / Q000150:complications / Q000188:drug therapy* / Q000473:pathology; D012307:Risk Factors; D014792:Visual Acuity
chemical_list: D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab
keywords: Macula; Retina